IGM Biosciences (NASDAQ:IGMS) Shares Gap Down to $20.96
IGM Biosciences (NASDAQ:IGMS) Shares Gap Down to $20.96
IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $20.96, but opened at $20.48. IGM Biosciences shares last traded at $21.21, with a volume of 556 shares trading hands.
IGM Biosciences，Inc.(纳斯达克代码：IGMS-GET Rating)的股价周三盘前大幅下跌。该股此前收于20.96美元，但开盘报20.48美元。IGM Biosciences的股票最新报21.21美元，总成交量为556股。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
IGMS has been the subject of several recent research reports. Bank of America initiated coverage on IGM Biosciences in a report on Monday, August 29th. They set a "buy" rating and a $34.00 price target for the company. Truist Financial lowered their target price on shares of IGM Biosciences from $74.00 to $37.00 and set a "buy" rating on the stock in a report on Tuesday, August 23rd. Guggenheim cut their price target on shares of IGM Biosciences to $40.00 in a report on Monday, August 15th. Finally, Robert W. Baird lowered their price objective on IGM Biosciences from $46.00 to $31.00 and set an "outperform" rating on the stock in a report on Wednesday, June 1st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $53.00.
IGMS是最近几份研究报告的主题。美国银行在8月29日星期一的一份报告中发起了对IGM Biosciences的报道。他们为该公司设定了“买入”评级和34.00美元的目标价。Truist Financial在8月23日(周二)的一份报告中将IGM Biosciences的股票目标价从74.00美元下调至37.00美元，并对该股设定了“买入”评级。古根海姆在8月15日星期一的一份报告中将IGM Biosciences的股票目标价下调至40.00美元。最后，罗伯特·W·贝尔德在6月1日星期三的一份报告中将IGM Biosciences的目标价从46.00美元下调至31.00美元，并对该股设定了“跑赢大盘”的评级。两名分析师对该股的评级为持有，七名分析师对该股的评级为买入。根据MarketBeat.com，该公司目前的平均评级为“中等买入”，平均目标价为53.00美元.
IGM Biosciences Price Performance
IGM生物科学价格表现
The business has a 50-day moving average price of $20.24 and a two-hundred day moving average price of $18.71.
该业务的50日移动均线价格为20.24美元，200日移动均线价格为18.71美元。
Insider Activity
内幕活动
In related news, insider Bruce Keyt sold 5,000 shares of IGM Biosciences stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $19.06, for a total transaction of $95,300.00. Following the completion of the sale, the insider now owns 39,489 shares in the company, valued at approximately $752,660.34. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 30,000 shares of company stock worth $622,107 over the last three months. 55.96% of the stock is currently owned by corporate insiders.
在相关新闻中，内部人士Bruce KEYT在一笔日期为9月6日(星期二)的交易中出售了5,000股IGM Biosciences股票。该股以19.06美元的平均价格出售，总成交金额为95,300.00美元。出售完成后，这位内部人士现在拥有该公司39,489股，价值约752,660.34美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在以下网址获得美国证券交易委员会网站。在过去的三个月里，内部人士已经出售了3万股公司股票，价值622,107美元。55.96%的股份目前由企业内部人士持有。
Institutional Trading of IGM Biosciences
IGM生物科学的制度性交易
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IGMS. American International Group Inc. increased its position in IGM Biosciences by 15.0% during the second quarter. American International Group Inc. now owns 4,684 shares of the company's stock worth $84,000 after purchasing an additional 612 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of IGM Biosciences by 9.6% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 9,100 shares of the company's stock worth $235,000 after buying an additional 800 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of IGM Biosciences in the 4th quarter worth $34,000. Rhumbline Advisers boosted its holdings in IGM Biosciences by 16.5% in the first quarter. Rhumbline Advisers now owns 9,222 shares of the company's stock valued at $247,000 after acquiring an additional 1,308 shares during the last quarter. Finally, Amalgamated Bank purchased a new stake in IGM Biosciences during the first quarter valued at about $36,000. Hedge funds and other institutional investors own 41.20% of the company's stock.
几家对冲基金和其他机构投资者最近增持或减持了IGMS的股份。美国国际集团在第二季度将其在IGM Biosciences的头寸增加了15.0%。美国国际集团目前持有该公司4,684股股票，价值84,000美元，此前该公司在上个季度又购买了612股。DekaBank Deutsche Girozentrale在第一季度增持了9.6%的IGM Biosciences股票。DekaBank Deutsche Girozentrale在上个季度又购买了800股，现在拥有9,100股该公司股票，价值23.5万美元。Point72 Hong Kong Ltd在第四季度购买了价值34,000美元的IGM Biosciences新股头寸。Rhumbline Advisers在第一季度将其在IGM Biosciences的持有量增加了16.5%。Rhumbline Advisers在上个季度增持了1,308股后，现在拥有9,222股该公司的股票，价值24.7万美元。最后，合并银行在第一季度购买了IGM Biosciences的新股份，价值约3.6万美元。对冲基金和其他机构投资者持有该公司41.20%的股票。
IGM Biosciences Company Profile
IGM生物科学公司简介
(Get Rating)
(获取评级)
IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).
IGM生物科学公司是一家生物技术公司，开发用于治疗癌症、传染病、自身免疫性疾病和炎症性疾病的免疫球蛋白M(IgM)抗体。该公司的主要候选产品是IGM-2323，这是一种双特异性IgM抗体，正处于第二阶段临床试验，用于治疗复发/难治性B细胞非霍奇金淋巴瘤(NHL)患者。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on IGM Biosciences (IGMS)
- General Mills: Superior Returns With Less Volatility
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- 免费获取StockNews.com关于IGM生物科学的研究报告(IGMS)
- 通用磨坊：波动性更小、回报更高
- 连续60年提高股息的3只防御性股票
- 3家航空公司股票陷入持有格局
- Roku股票下跌，但并未出局
- 福特在第三季度发出警告后是否正在反弹
Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受IGM《生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对IGM Biosciences和相关公司的最新新闻和分析师评级的每日简明摘要。